Last updated 2026-07-20
- Raised $3.5M Seed round, Feb 2026
Total raised
$3.5M
Stage
Pre-Funding
Founded
2026
Headcount
1
HQ
null, Israel
Sector
Health Tech & Life Sciences
About
NeuroVectis is an Israeli biotechnology company focused on developing a revolutionary medical solution for Parkinson's disease. The company utilizes an autologous tissue-engineering platform to create living and functional neural implants from the patient's own tissues (abdominal fat and blood platelets) to restore natural dopamine production and provide a long-term solution for Parkinson's.
Funding history · 1 round · $3.5M total
2026-02
Seed
$3.5M
Q&A
- What is NeuroVectis's primary focus?
- NeuroVectis is developing an autologous tissue-engineered therapy for Parkinson’s Disease and Parkinsonism.
- When was NeuroVectis founded?
- NeuroVectis was founded in January 2026.
- What is the current employee count for NeuroVectis?
- NeuroVectis currently has 1-10 employees.
- What is NeuroVectis's current funding stage?
- NeuroVectis is currently in the Pre-Funding stage.
- What is the core technology behind NeuroVectis's therapy?
- NeuroVectis's program intends to use patient-derived cells, extracellular matrix, hydrogel, and engineered neural tissue to create a living implant.
- What is the goal of NeuroVectis's regenerative therapy?
- The therapy is designed to restore dopamine production and support brain-tissue repair, rather than only manage symptoms of Parkinson's disease.
- Where is NeuroVectis headquartered?
- NeuroVectis is headquartered in Ness Ziona, Israel.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Business model
B2B
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2026-2 |
|---|---|
| Employees (exact) | 1 |